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Abstract 
The role of androgens in prostate cancer is obvious due to the fact that androgen signalling is the main regulator of 
prostate growth and function. Androgen deprivation therapy is a mainstay treatment for advanced prostate cancer. 
However, prostate cancer often becomes androgen‑independent, which in consequence leads to lethal and incur‑
able disease. In addition, oestrogens play a crucial role in prostate cancer, especially in elder men in whom the overall 
ratio of oestrogens to androgens is increasing. This review summarizes the current knowledge on molecular mecha‑
nisms through which oestrogens are involved in prostate cancer development. We focused on commonly alternated 
molecular signalling pathways contributing to tumourgenesis in prostate cancer.
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Prostate cancer
Prostate cancer (PCa) is one of the most common malig-
nance in men in developing countries. In Western coun-
tries it is the second cause of death in men, and in the 
majority of cases it is associated with metastases (Bishop 
et  al. 2015). In recent years the incidences of prostate 
cancer have been increasing with simultaneous increase 
in survival rate of the diagnosed patients (Wojciechowska 
et al. 2015). The progress made in treatment of this dis-
ease is probably associated with detection of prostate-
specific antigen (PSA) which is currently used as a 
prognostic marker detected in patients’ serum (Stelmach 
et  al. 2011). Although many research studies have been 
carried out on prostate cancer, detailed molecular mech-
anism has not been revealed. It is known that age, race, 
ethnicity or place of living might be causative factors for 
prostate cancerogenesis. Also diet and lifestyle are recog-
nized as carcinogenic factors (Mahmoud et al. 2015). PCa 
could be classified on the basis of different morphologic 
types, of which the most common is adenocarcinoma 
derived from epithelium, neuroendocrine tumours, 
sarcomas and lymphomas (Wojciechowska et  al. 2015). 
Treatment of the early stages of PCa are usually focused 
on deprivation of androgens, known as: androgen depri-
vation therapy (ADT). In advanced stages prostate can-
cer cells begin to be androgen independent and present 
higher metastatic potential (Suva et al. 2011).
Oestrogens and oestrogens receptors
Oestrogens play a crucial role in human development, 
maintaining sexual and reproductive functions of the 
organism, as well as influencing the function of car-
diovascular, immune, skeletal and central nervous sys-
tem. The most potent oestrogen produced by the body 
is 17β-estradiol (E2) (Heldring et  al. 2007). Neverthe-
less, clinical evidence obtained by Huggins and Hodges 
showed that oestrogens can influence prostate can-
cer by inhibiting tumour growth (Huggins and Hodges 
1972). Nowadays, oestrogens are used in prostate cancer 
therapy to reduce follicle-stimulating hormone (FSH) 
production and decrease stimulation of hypothalamic 
pituitary by luteinizing hormone (LH), which in conse-
quence reduces androgen synthesis. Although the usage 
of oestrogens in PCa therapy seems to be favourable, 
castrate-resistant prostate cancer cells (CRPC) can over-
come the mechanisms mentioned above and progress in 
the disease. Moreover, oestrogen therapy has numerous 
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cardiovascular and thrombotic side effects that reduce its 
clinical use as an alternative to castration (Christoforou 
et al. 2014).
Cellular signalling of oestrogens is triggered by oestro-
gen receptors (ERs) α (ERα) and β (ERβ) which are the 
members of nuclear receptor superfamily (NR) of tran-
scription factors (Christoforou et  al. 2014). In prostate 
ERβ is present in epithelial cells, whereas ERα in stromal 
cells (Powell et  al. 2012). ERs contain evolutionary con-
served structurally and functionally distinct domains, 
characteristic for the family of nuclear receptors (Fig. 1). 
DNA-binding domain (DBD) involved in DNA recog-
nition is the central and the most conservative domain. 
Ligand binding takes part at COOH-terminal multifunc-
tional ligand-binding domain (LBD). The most variable 
domain is NH2-terminal domain which is also not con-
served. Two distinct activation sites: AF-1 and AF-2 ena-
ble transcriptional activation (Heldring et al. 2007).
ERα and ERβ are products of genes localized on dif-
ferent chromosomes. They have the ability to dimerize 
with full length ERα and repress AF-1 mediated activ-
ity (Wang et al. 2005). In humans five forms of ERβ were 
identified ERβ1, ERβ2, ERβ4 and ERβ5 in normal prostate 
cell (Fig. 2; Santamaria-Martinez et al. 2008). Recently, it 
was suggested that only ERβ1 isoform may be fully func-
tional, due to the fact that it is the only isoform which 
may form homodimers or take part in recruitment of 
coregulatory proteins (Leung et al. 2006). More attention 
should be placed on ERβ2 and ERβ5 isoforms. They have 
the same sequence as ERβ1 from exons 1–7 and contain 
extra sequences with lost AF-2 domain function (Leung 
et al. 2010). Moreover they can form heterodimers with 
ERβ1 isoform after oestrogen stimulation (Leung et  al. 
2006) or with ERα and through this silence signalling of 
ERα (Ogawa et al. 1998).
In recent years more attention is paid to oestrogen 
receptors in prostate cancer indicating that ERα and 
ERβ may play an opposite role in prostate cancer. Firstly, 
it was suggested that ERα stimulates cell proliferation 
and transcription and has opposing role to ERβ whose 
expression is lost during the progression of the disease 
(Fixemer et al. 2003). Currently, the antiproliferative role 
of ERβ is not so obvious due to research presenting that 
ERβ2 and ERβ5 isoforms have tumour-promoting roles 
(Nelson et al. 2014). ERα-knockout mice do not develop 
prostate cancer after stimulation of testosterone or oes-
trogens, whereas ERβ-knockout mice do, similarly to the 
wild type mice (Ricke et  al. 2008). Furthermore, ERβ1 
might complex with AR and cause a transcription of AR-
related genes in PCa, what might explain the fact of ele-
vated ERβ expression in HNPC, corresponding to lower 
survival of patients (Nelson et  al. 2014). Nevertheless, 
many research studies have been conducted to reveal the 
detailed molecular mechanism of oestrogen receptors 
function in PCa.
In this article we reviewed the molecular signalling 
pathways in which oestrogen receptors are involved 
in prostate cancer cells (Table  1): cell proliferation and 
apoptosis as the two pathways mainly altered in car-
cinogenesis by gene mutations or improper regulation of 
gene expression (Dey et al. 2012) what can be confirmed 
by the fact that in human prostate tumours an increase 
in apoptosis and simultaneous decrease in proliferation 
are found 1–7 days after castration and retrieval of these 
markers in some patients is possible after 10 days (Ohl-
son et  al. 2005); then epithelial to mesenchymal transi-
tion (EMT) and cell invasiveness as the two processes 
mainly responsible for metastases which enables pros-
tate cancer cells to engraft in the bone marrow places, 
as well as the fact that the molecular crosstalk between 
the prostate tumour and bone stroma in which EMT 
genes participate is a target of prostate cancer therapies 
(Smith and Bhowmick 2016); and the chronic inflamma-
tion frequently detected in prostate biopsies in patients 
with increased prostate specific antigen (PSA). Moreo-
ver, it was showed that chronic inflammation in benign 
prostate tissue contributes to high-grade prostate cancer 
Fig. 1 Schematic representation of oestrogen receptors isoforms: α 
(ERα) and β (ERβ). AF‑1 and AF‑2: distinct transcription activation sites; 
DBD—DNA‑binding domain; LBD—ligand‑binding domain; NH2– 
and –COOH are terminal regions of protein; ERα is 595 amino acids 
length, ERβ 530 amino acids length
Fig. 2 Schematic structure of oestrogen receptor β (ERβ) isoforms. 
First six exons are the same in different isoforms. All isoforms share 
the same DNA‑binding domain (DBD) but differ in ligand‑binding 
domains (LBD). On the right side the length of amino acids products 
is presented
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and novel biomarkers for predicting tumour progression 
due to prostatic inflammation in prostate cancer patients 
were investigated (Stark et al. 2015).
Prostate cancer cell proliferation
The role of ERα in prostate cancer cell proliferation is 
well documented (Fig. 3). Mice lacking ERα did not pre-
sent aggressive tumour phenotype, contradictory to mice 
lacking ERβ (Slusarz et  al. 2012). PTEN-deficient mice 
which are used in prostate cancer studies showed signifi-
cantly increased expression of ERα in regions were cell 
proliferation was elevated. Depletion of ERα caused a sig-
nificant decrease in the size of prostate cancer cell colo-
nies without changing their number. Mitogen-activated 
protein kinases (MAPK) activity and phosphoinositide 
3-kinase (PI3K) signalling pathways are sustained by ERα 
in prostate cancer (Takizawa et al. 2015). Fujimura et al. 
(2014) found a relationship between biochemical recur-
rence, prognoses and ERα expression. ERα counterparts 
in oestrogen induced translocation of prohibitin (PHB) 
known to have a significant effect on cell senescence 
and tumour cell suppression through modulation of 
Table 1 Summarized biochemical pathways and genes involved in oestrogen signalling in prostate cancer




Oncogenes BMI‑1 ERβ Mak et al. (2006)
Twist ERβ2 Dey et al. (2012)
Suppressors PTEN ERα Takizawa et al. (2015)
MAPK ERα Takizawa et al. (2015)
Cell cycle control p21 ERβ Colciago et al. (2014)
CCND1 ERβ Nakamura et al. (2013)
c‑Myc ERβ2 Dey et al. (2012)
Signaling pathways PI3 K ERα Takizawa et al. (2015)
mTOR ERα and ERβ Wang et al. (2014)
Apoptosis
Proapoptotic Bax ERβ Cheng et al. (2004)
Cleaved caspase‑3 ERβ Cheng et al. (2004)
p‑53 ERs Kanagaraj et al. (2007)
FOXO3 and PUMA ERβ Dey et al. (2014)
Pro/antiapoptotic TGF‑β1 ERs Chipuk et al. (2001)
Epithelial‑mesenchymal transition (EMT)
↓EMT PHD2/EGLN1 ERβ1 Mak et al. (2006, 2010)
HIF1‑α ERβ1 Mak et al. (2006, 2010)
Snail1 ERβ1 Mak et al. (2006, 2010)
Runx 2 ERβ2 Dey et al. (2012)
TGF‑β1 ERβ Hu et al. (2015)
E‑cadherin ERβ Hu et al. 2015
Thbs2 ERα Slavin et al. (2014)
MMP3 Slavin et al. (2014)
↑EMT SOX4 ERβ Mak et al. (2010)
Twist1 ERβ2 Dey et al. (2012)
c‑Myc ERβ2 Dey et al. (2012)
HIF‑1α ERβ2 and ERβ5 Dey et al. (2015)
Runx 2 ERβ1 Dey et al. (2012)
NEAT‑1 ERβ Chakravarty et al. (2014)
Chronic inflammation
↑ HIF‑1α ERα Ravenna et al. (2009, 
2014)
NF‑κB ERα Ravenna et al. (2009, 
2014)
Page 4 of 9Kowalska and Piastowska‑Ciesielska  SpringerPlus  (2016) 5:522 
retinoblastoma protein (pRB) binding with transcription 
factors family (E2F) complex which leads to repression 
of pRb-E2F-associated transcription and cell prolifera-
tion. Silencing ERα using siRNA approach was able to 
suppress PC3 (human prostate cancer adenocarcinoma 
cell line) cells proliferation and translocation of PHB 
from mitochondria to the nucleus (Dong et  al. 2013). 
Hariri et  al. (2015) have recently shown that low doses 
of toremifene, a ERα blocker, causes necrosis with high 
expression of ERα on the stromal surface of the PC3M 
(cell line derived from a liver metastasis of PC-3 intras-
pleenic injection in nude mice) cancer cells.
Many research studies are focused on detailed molecu-
lar mechanism of ERβ action in prostate cancer. More-
over, it seems that antiproliferative function of all ERβ 
isoforms is not so obvious. In vitro models of prostate 
adenocarcinoma expressing only ERβ showed that stim-
ulation of estradiol caused significant reduction of cell 
proliferation (Corey et al. 2002). Interestingly, cell trans-
fection with ERβ1 or ERβ2 revealed that only ERβ1 iso-
form inhibits proliferation of prostate cancer cells (Dey 
et al. 2012). Cell cycle genes play an important role in the 
control of cell proliferation and tumourgenesis. Cyclin 
D1 (CCND1) is overexpressed in many types of human 
cancer including prostate cancer. Interaction between 
androgens and cell cycle associated proteins was reported 
by Perry and Tindall in 1996. Like androgens, oestrogens 
have a capability to modulate cell cycle progression. ER 
inhibitor ICI 182,780 was reported to influence CCND1 
expression and modulate progression to late G1 cell cycle 
phase (Santamaria-Martinez et al. 2008). The studies by 
Nakemura et  al. (2013) revealed that oestrogens modu-
late CCND1 expression trough ERβ via increasing FBJ 
murine osteosarcoma viral oncogene homolog (FOS) and 
jun proto-oncogene (JUN) expression in prostate adeno-
carcinoma PC3 cell line. Cyclin D1-mediated cell cycle 
pathway might be also modulated by serum/glucocorti-
coid regulated kinase family member 3 (SGK3)-andro-
gen receptor (AR) expression. Wang et  al. documented 
that in AR-positive cells both ER receptors are involved 
in regulation of cell cycle through mammalian target 
of rapamycin (mTOR) signalling pathway (Wang et  al. 
2014). Nuclear ERβ2 isoform was reported to have an 
oncogenic role due to its ability to increase proliferation 
and expression of twist family bHLH transcription fac-
tor 1 (Twist1) and v-myc avian myelocytomatosis viral 
oncogene homolog (c-Myc) in PC3 and 22Rv1 carcinoma 
human prostate cancer cell lines (Dey et al. 2012). Endog-
enous activation of ERβ in PC3 and DU-145 (prostate 
carcinoma derived from metastatic site—brain) cells was 
reported to cause an increase in cyclin-dependent kinase 
inhibitor 1A (p21) expression and cell cycle arrest indi-
cating that control of proliferation might be governed by 
cell cycle modulation (Colciago et al. 2014).
In males ERβ ligand 3β-Adiol which is a product of 
5α-reduction of testosterone to 5α-dihydrotestosteron 
(DHT), is present in high levels. Its binding to ERβ recep-
tor in prostate cancer cells is sufficient to inhibit PCa 
proliferation with simultaneous inhibition of migration 
and invasiveness of PCa cells (Dondi et al. 2010). Another 
molecular mechanism of cell cycle modulation caused by 
ERβ was proposed by Mak et al. They postulated that ERβ 
is repressed in prostate cancer through polycomb com-
plex protein BMI-1 (BMI-1), which is induced by phos-
phatase and tensin homolog (PTEN) deletion. BMI-1 is 
a well-known oncogene regulating cell proliferation and 
senescence in prostate tumourgenesis (Mak et al. 2006).
Apoptosis of prostate cancer cells
Aside from the role of ERβ in inhibiting PCa cell prolif-
eration and growth, many studies have shown that this 
oestrogen receptor may be involved in regulation of 
programmed cell death (Fig. 4). Cheng et al. (2004) sug-
gested that ERβ is a stronger regulator of cell growth that 
ERα in prostate cancer. Moreover, they presented that 
introduction of ERβ to DU-145 cell line led to a strong 
increase in pro-apoptotic protein BCL2-associated X 
Fig. 3 Summarized cell signalling pathways in which oestrogen 
receptor α (ERα) takes part (detailed description presented in the text) 
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protein (Bax) and peri-nuclear expression of cleaved 
caspase-3. ERβ might also downregulate c-FLIP (cellular 
FLICE (FADD-like IL-1β-converting enzyme)-inhibitory 
protein) promoter by binding to Sp1 site or by modula-
tion of Sp1/Sp3 ratio through competitive DNA bind-
ing, and then promote apoptosis in prostate cells (Yun 
et  al. 2015). Miro et  al. (2011) suggested that oxidative 
stress might be a causative factor in apoptosis. The effect 
of β-estradiol on prostate cells in the case of oxidative 
stress is dependent on ERα/ERβ ratio and might cause 
an increase in mitochondrial production of reactive-oxy-
gen species (ROS) by repressing the uncoupling proteins 
(UCPs), which is consistent with previously reported ERα 
pro- and ERβ antioncogenic effect. UCPs are involved 
in the maintenance of mitochondrial membrane poten-
tial and ROS production (Valle et al. 2010). It was shown 
that prolonged increase in Ca2+ concentration may lead 
to apoptosis. 17β-estradiol through ERs can cause a con-
centration-dependent increase in Ca2+ concentration in 
PC3 cells, thus modulate the activity of Ca2+-dependent 
enzymes and tumourgenesis of prostate tissue (Huang 
and Jan 2001). Kanagaraj et  al. (2007) found that estra-
diol causes apoptosis in PC3 cells due to reduced matrix 
metalloproteinase (MMP) level and increased Insulin-
like growth factor-binding protein 3 (IGFBP-3), which 
was reported to induce apoptosis through tumour pro-
tein p53 (p53)-dependent manner. Apoptosis in prostate 
cancer might be also triggered by ERβ-induced increase 
in transcription of forkhead box O3 (FOXO3a)-tran-
scription factor known as a tumour suppressor. Increased 
FOXO3a transcription then causes an increase in PUMA 
expression (a pro-apoptotic factor p53-upregulated 
modulator of apoptosis) and triggers apoptosis in pros-
tate cancer cells (Dey et  al. 2014). In epithelial prostate 
cells TGF-β1 has been shown to induce apoptosis via 
release of cytochrome c (Chipuk et al. 2001). There is also 
evidence presenting that during tumour progression the 
inhibitory effect of TGF-β1 may promote tumour growth 
via its angiogenic effect. Brodin et  al. (1999) suggested 
that activation of SMAD family member 2 (Smad2) and 
upregulation of SMAD family member 3, 4, 6 and 7 
(Snad3, Smad4, Smad6 and Smad7) are associated with 
induction of apoptosis in both normal and cancer pros-
tate cells.
EMT and cell invasiveness
It is well known that high grade PCa lose their epithe-
lial phenotype and show mesenchymal characteristics, 
such as expression of vimentin and vascular endothelial 
growth factor (VEGF), loss of E-cadherin and increase 
in expression of hypoxia-inducible factor 1α (HIF-1α) 
(Christoforou et  al. 2014). The sex determing region 
Y-box (SOX4) is a transcription factor commonly over-
expressed in PCa. Estradiol up-regulates SOX4 expres-
sion by formation of ERβ and AR protein complex. 
Moreover, clinical data reported in China suggested that 
overexpression of SOX4 is significantly associated with 
ERβ expression and EMT in patients (Yang et al. 2015). 
ERβ1 was shown to inhibit EMT by upregulating propyl 
hydroxylase domain 2 (PHD2/EGLN1) and decreasing 
hypoxia inducible factor 1 alpha subunit (HIF-1α) levels, 
as well as repressing transcription of vascular endothe-
lial growth factor A (VEGF-A) (Fig. 5). Mak et al. (2010) 
suggested that ERβ1 regulates snail family zinc finger 1 
(Snail1) via the regulation of glycogen synthase kinase 
3 (GSK-3β) activity, an enzyme that is crucial for regu-
lation of Snail1 localization and stability (Mak et  al. 
2006, 2010). On the other hand ERβ2 was reported to 
increase invasiveness of PCa cells trough expression 
of Twist1 and c-Myc (Dey et  al. 2012). ERβ2 and ERβ5 
were shown to stabilize HIF-1α protein and induce 
hypoxic gene expression indicating its oncogenic effect 
in PCa (Dey et al. 2015). In vitro studies on PC3 cell line 
demonstrated that ERβ1 was able to repress the expres-
sion of Runx2, which is known to be involved in bone 
metastases in prostate cancer, whereas ERβ2 isoforms 
triggered a contradictory effect (Dey et al. 2012). Slater 
et  al. (2002) presented data suggesting that increase in 
ERβ receptor might be simultaneous with increase of 
E-cadherin expression and decrease of TGF-β1 in pros-
tate epithelium. Similar effect was observed by Mak et al. 
(2010) who noted that TGFβ1 signalling decreased ERβ 
expression in both AR-dependent and AR-independ-
ent manner. Moreover, ERβ knock down using shRNA 
caused a significant increase in EMT (Mak et al. 2010). 
Fig. 4 Summarized cell signalling pathways in which oestrogen 
receptor β (ERβ) induces apoptosis in prostate cancer. ERβ through 
different pathways induces cell cycle arrest and apoptosis (detailed 
description is presented above in the text)
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Another protein involved in EMT in prostate cancer 
might be periostin which is also known as osteoblast-
specific factor 2. It was confirmed that periostin is 
induced by TGF-β/STAT3/Twist1 pathway and partici-
pates in TGF-β-induced EMT (Hu et al. 2015). Modula-
tors of oestrogen receptors were shown to decrease cell 
migration and this effect was reversed by antioestro-
gens, indicating that anti-migratory action of phytoes-
trogens is directly associated with ERs (Piccolella et  al. 
2014). It is known that loss of ERβ may correlate with the 
development of poorly differentiated PCa (Slusarz et al. 
2012). Mak et  al. (2015) suggested a molecular mecha-
nism associated with repression of ERβ in PCa. ERβ loss 
is caused by PTEN deletion, which is one of the most 
common genetic mutations in prostate cancer. ERβ tran-
scription is diminished by BMI-1 which is induced by 
PTEN deletion. This mechanism cooperates with above-
mentioned HIF-1/VEGF signalling pathway altered in 
prostate cancer cells (Mak et al. 2015). Another mecha-
nism associated with ERs in prostate cancer may involve 
interaction of ERs with nuclear paraspeckle assembly 
transcript 1 (NEAT-1), a transcriptional regulator which 
contributes to tumourgenesis. Chakravarty et al. (2014) 
showed that ERα transcriptionally regulates NEAT1 and 
promotes prostate tumour progression both in vitro and 
in  vivo. Prostate cancer invasion might be suppressed 
by cancer-associated fibroblasts (CAFs) in which ERα 
was reported to modulate thrombospondin 2 (Thbs 2) 
and matrix metalloproteinase 3 (MMP-3). ERα in CAFs 
probably decreases invasiveness through decreasing 
tumour angiogenesis (Slavin et al. 2014).
Chronic inflammation in prostate cancer
ERs might be also associated with inflammation in pros-
tate cancer. Yatkin et  al. (2009) suggested that reduced 
androgen/oestrogen ratio might induce inflammation in 
rat prostate. Harris et al. (2000) suggested that oestrogens 
play a proinflammatory role and high androgen concen-
tration plays a protective role. They showed that 4  days 
oestrogen treatment caused an increase in interleukin-1 
beta, 6 and inflammatory protein 2-alpha (IL-1β, IL-6, 
MIP-2) and inducible nitric oxide synthase (iNOS) lev-
els in in vivo model. Moreover, oestrogens effect on cell 
inflammation is probably associated with ERα activity. 
Prins et al. (2001) observed that after treatment with oes-
trogens inflammation was present only in ERβ-knockout 
mice, but not in ERα-knockout mice. It was suggested 
that on the molecular level only ERα and epidermal 
growth factor receptor (EGFR) expression correlates 
with the levels of all proinflammatory molecules, and 
HIF1-α and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-kB) are the master regulators of 
Fig. 5 Schematic cell signalling pathways in which different isoforms of oestrogen receptor β (ERβ) might be involved in dualistic action in prostate 
cancer. Different signalling pathways might be associated with different homo‑ and hetero‑dimerization of ERβ isoforms (not presented in the 
figure). Detailed description presented above in the text
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hypoxia and inflammation, respectively, in prostate can-
cer cell lines (Ravenna et al. 2009, 2014).
Oestrogens in prostate cancer therapy
Androgen deprivation therapy (ADT) is recommended 
for the treatment of advance prostate cancer patients (Yu 
et al. 2015). Oestrogens were used as a gold standard in 
prostate cancer therapy years ago. Many research studies 
showed that oral oestrogens might increase cardiovascu-
lar toxicity which in association with the age of patients 
limits the usage of oestrogens caused by the effect of the 
first-pass hepatic metabolism on coagulation (Stein et al. 
2012; Langley et al. 2013). Nevertheless, nowadays more 
attention is paid to oestrogens, due to the fact that gon-
adotropin-releasing hormone (GnRH) agonists used as 
a standard treatment have oestrogen-deficiency related 
side effects (Yu et al. 2015; Stein et al. 2012). It seems that 
avoidance of the oral administration might limits cardio-
vascular side effects associated with oestrogens. Thus, 
parenteral administration of oestrogens might be use-
ful in prostate cancer therapy and might be an alterna-
tive to current standard therapy (Langley et al. 2013). The 
usage of diethylstilbestrol (DES) a synthetic oestrogen 
was reported to possess acceptable toxicity and might 
be considered for further clinical studies (Wilkins et  al. 
2012). Tormifene which belong to second-generation of 
selective oestrogen receptor modulators (SERMs) was 
reported to decrease the incidence of new cardiovas-
cular side effects in men younger than 80  years old in 
ADT treated patients in 80 mg dose (Smith et al. 2011). 
On the other hand for the dose of tormifene 20  mg no 
beneficial effect was observed in another study (Taneja 
et al. 2013). Clinical significance was also established for 
2-methoxyoestradiol (2ME2) which possesses anti-angi-
ogenic and anti-proliferative characteristics for patients 
with CRPC with no beneficial effect observed (Harrison 
et al. 2011). Interestingly, its analogue ENMD-1198 was 
recommended for phase II clinical studies as beneficial 
for patients (Zhou et al. 2011). The agonist of ERα GTx-
758 significantly decreased oestrogen deficiency side 
effects during ADT, although it increases the incidence of 
venous thromboembolism (VTE) (Yu et al. 2015). Thus, 
more clinical studies should be carried out to exclude 
potential side effects associated with known oestrogens 
or to determine the potential usage of the new ones.
Conclusions
In recent years there is a growing body of evidence that 
oestrogens play crucial role in prostate tumourgenesis. 
Here we presented data showing that oestrogen, act-
ing via its receptors, regulates various cellular processes 
including: proliferation, differentiation, apoptosis, EMT, 
invasiveness and chronic inflammation in prostate cancer 
cells. It seems that ERα possesses oncogenic role in pros-
tate cancer, whereas ERβ suppressive role has been dis-
putable so far. Now, many research studies have shown 
that ERβ isoforms might act differently in prostate can-
cer indicating that its role is pleiotropic. Taken together, 
oestrogen plays an important role in prostate carcinogen-
esis through direct or indirect participation in molecular 
mechanism which are crucial for tumourgenesis, i.e.: pro-
liferation, cell cycle control, apoptosis or EMT. Further 
studies are needed to explain all molecular mechanisms 
of oestrogen signalling in prostate cancer due to their 
importance in developing new approaches to prostate 
cancer treatment.
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retinoblastoma protein; PSA: prostate‑specific antigen; PTEN: phosphatase and 
tensin homolog; PUMA: pro‑apoptotic factor p53‑upregulated modulator of 
apoptosis; ROS: reactive‑oxygen species; SERMs: selective oestrogen receptor 
modulators; SGK3: serum/glucocorticoid regulated kinase family member 
3; Smad2: SMAD family member 2; Smad3: SMAD family member 3; Smad4: 
SMAD family member 4; Smad6: SMAD family member 6; Smad7: SMAD family 
member 7; Snail‑1: snail family zinc finger 1; SOX4: sex determing region Y‑box; 
TGF‑β1: transforming growth factor beta; TGF‑β1: transforming growth factor 
β1; Thbs 2: thrombospondin 2; Twist‑1: twist family bHLH transcription factor 
1; UCPs: uncoupling proteins; VEGF: vascular endothelial growth factor; VEGF‑
A: vascular endothelial growth factor A; VTE: venous thromboembolism.
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